<DOC>
	<DOC>NCT02689921</DOC>
	<brief_summary>This is a prospective, single-arm, phase II study of 32 evaluable patients treated with NEOADjuvant Aromatase inhibitor and Pertuzumab/Trastuzumab (NEOADAPT) without chemotherapy for hormone receptor positive (HR+), [i.e. Estrogen Receptor positive (ER+) and/or Progesterone Receptor positive (PR+)] HER2+ localized, non-metastatic stage I - IIb breast cancer.</brief_summary>
	<brief_title>NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Ability to provide signed, written informed consent Histologically or cytologically confirmed nonmetastatic adenocarcinoma of the breast (stage III) Candidate for curativeintent treatment ER+ and/or PR+ and HER2positive (Fluorescence In Situ Hybridizationpositive or 3+ by Immunohistochemistry staining) Life expectancy greater than 5 years Left Ventricular Ejection Fraction &gt; 50% at baseline (within 30 days of day 0) Eastern Cooperative Oncology Group performance status ≤2 Absolute Neutrophil Count &gt;1000/µL Platelets ≥50,000/µL Hemoglobin &gt;8.0 g/dL, Creatinine ≤3.0 x upper limit of normal (ULN) Bilirubin ≤3.0 x ULN Aspartate aminotransferase or Alanine aminotransferase &lt;5.0 x ULN Negative serum pregnancy test for women &lt;12 months after the onset of menopause unless surgically sterilized Agreement by women of childbearing potential and male participants with partners of childbearing potential to use a "highly effective", nonhormonal form of contraception or two "effective" forms of nonhormonal contraception by the patient and/or partner. Active infection Presence of known metastases (stage IV disease) Pregnant or lactating women Prior chemotherapy or radiation therapy for the primary breast cancer Concomitant malignancies or previous malignancies within the last 5 years except adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. History of significant cardiac disease, cardiac risk factors or uncontrolled arrhythmias Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary or metabolic disease including diabetes, wound healing disorders, ulcers or bone fractures) Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipated need for major surgery during the course of study treatment Current known infection with Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV) or Hepatitis C Virus (HCV) Receipt of intravenous antibiotics for infection within 14 days prior to receiving study treatment Current chronic daily treatment with corticosteroids (dose &gt;10 mg/day methylprednisolone equivalent) except inhaled steroids Known hypersensitivity to any of the study drugs Assessment by the investigator to be unable or unwilling to comply with the requirements of the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>